VEGFR-3 fusion proteins
View Patent ↗The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided.
1. A purified fusion protein comprising a first binding unit polypeptide connected to a heterologous peptide,
wherein the amino acid sequence of the first binding unit polypeptide consists of an amino acid sequence at least 95% identical to a VEGFR-3 fragment consisting of a portion of SEQ ID NO: 6,
wherein the amino-terminal amino acid of the VEGFR-3 fragment is selected from the group consisting of positions 1-47 of SEQ ID NO: 6,
wherein the carboxy-terminal residue of the VEGFR-3 fragment is selected from the group consisting of positions 211 to 247 of SEQ ID NO: 6, and
wherein the VEGFR-3 fragment and the purified fusion protein bind human VEGF-C.
2. The fusion protein according to claim 1 , wherein the heterologous peptide comprises an immunoglobulin constant domain fragment.
3. The fusion protein according to claim 2 , wherein the amino acid sequence that is at least 95% identical to the VEGFR-3 fragment is selected from the group consisting of SEQ ID NOS: 36 and 38.
4. The fusion protein according to claim 1 , wherein the fusion protein further comprises a signal peptide.
5. The fusion protein according to claim 4 , wherein the signal peptide directs secretion of the fusion protein from a cell that expresses the fusion protein.
6. The fusion protein according to claim 1 , wherein the VEGFR-3 fragment has an amino acid sequence selected from the group consisting of positions 1-226 and 1-229 of SEQ ID NO: 6.
7. A binding construct comprising the fusion protein according to claim 1 operatively connected with a second binding unit polypeptide that binds at least one growth factor selected from the group consisting of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, PlGF, PDGF-A, PDGF-B, PDGF-C, and PDGF-D.
8. The binding construct of claim 7 , wherein the second binding unit polypeptide is selected from the group consisting of a polypeptide comprising a vascular endothelial growth factor receptor extracellular domain fragment, a platelet derived growth factor receptor extracellular domain fragment, and a polypeptide comprising an antigen binding fragment of an antibody that immunoreacts with the at least one growth factor.
9. A composition comprising a fusion protein according to claim 1 in a pharmaceutically acceptable carrier.
10. A purified fusion protein comprising an amino acid sequence of a VEGFR-3 fragment connected to a heterologous peptide, said VEGFR-3 fragment consisting of a portion of SEQ ID NO: 6,
wherein the amino-terminal residue of the VEGFR-3 fragment is selected from the group consisting of positions 1 to 47 of SEQ ID NO: 6,
wherein the carboxy-terminal residue of the VEGFR-3 fragment is selected from the group consisting of positions 211 to 247 of SEQ ID NO: 6, and wherein the VEGFR-3 fragment and the purified fusion protein bind human VEGF-C.
11. The fusion protein according to claim 1 or 10 , wherein the VEGFR-3 fragment has a carboxy-terminal amino acid selected from the group consisting of positions 226 and 229 of SEQ ID NO: 6.
12. The fusion protein according to claim 10 , wherein the heterologous peptide comprises an immunoglobulin constant domain fragment.
13. The fusion protein according to claim 12 , wherein the fusion protein further comprises a signal peptide that directs secretion of the fusion protein from a cell that expresses the fusion protein.
14. A binding construct comprising the fusion protein according to claim 10 operatively connected with a second polypeptide that binds at least one growth factor selected from the group consisting of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-L, PlGF, PDGF-A, PDGF-B, PDGF-C, and PDGF-D.
15. The binding construct of claim 14 , wherein the second polypeptide is selected from the group consisting of a polypeptide comprising a vascular endothelial growth factor receptor extracellular domain fragment, a platelet derived growth factor receptor extracellular domain fragment, and a polypeptide comprising an antigen binding fragment of an antibody that immunoreacts with the at least one of said growth factors.
16. A composition comprising a binding construct according to claim 15 in a pharmaceutically acceptable carrier.
17. A composition comprising a fusion protein according to claim 10 in a pharmaceutically acceptable carrier.